Presenting Companies
Akridata delivers next-generation AI solutions for visual inspection in manufacturing. Our platform empowers data science and quality teams to curate and manage large datasets, build state-of-the-art AI models, and deploy AI-assisted human inspection systems that enhance accuracy and throughput. Trusted by leading manufacturers in automotive, medical devices, and industrial sectors, Akridata helps streamline quality control with precision, speed, and scale.
Amplifi Vascular makes small veins BIG! Amplifi Vascular is initially focused on the current dialysis access crisis into a dialysis access “opportunity" with a first-of-its-kind Vein Dilation System, a platform technology with reach to all forms of surgical bypass and limb ischemia. The company has obtained IDE approval, Breakthrough Designation and will commence their US Study in early January, 2026.
Anaconda Biomed S.L. is a Barcelona based medical device start-up co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company is developing the next generation of catheters to perform safe and efficient mechanical thrombectomies.
Founded by seasoned medtech executives and venture-backed since 2020, Arga Medtech is transforming cardiac electrophysiology with its groundbreaking Coherent Sine-Burst Electroporation (CSE) technology. The company’s unique all-in-one catheter system streamlines complex ablation procedures for atrial fibrillation (AF) and other arrhythmias, delivering efficient, precise, and tissue-specific ablation with exceptional safety. Optimized for persistent AF and cases requiring ablation beyond pulmonary vein isolation, Arga’s platform enables electrophysiologists to perform advanced lesion sets and tailored strategies in a single procedure. Early clinical data on the treatment of atrial fibrillation show outstanding efficacy and zero major complications, positioning Arga’s CSE system to set a new standard in electrophysiology. With strong funding and leadership, Arga is advancing pivotal IDE trials and scaling towards commercialization.
AseptiScope, Inc. is a privately funded, San Diego-based clinical innovation company in early commercial phase. Led by a team of clinical experts, medical researchers, and practicing physicians, the company's mission is to design, develop, manufacture, and commercialize novel solutions that provide "Infection Protection for Clinician & Patient." Its flagship product, The DiskCover System, is the first and only technology to provide an evidence-based, touch-free solution to stethoscope contamination, a vector that touches US patients 5 billion times every year.
Assistive Technology Development (ATDev) creates robotic and telehealth-enabled devices that empower people to live more independently. Our flagship product, Reflex, is a lightweight knee rehabilitation system that provides both passive and active therapy at home while keeping patients and clinicians connected through real-time data. Founded by engineers, clinicians, and wheelchair users, ATDev’s mission is simple: mobility for all. We are redefining recovery through accessible, high-quality technology that restores freedom and dignity to millions.
Axtion Independence Mobility Inc. are the creators of the award winning RAYMEX® Lift, a portable, personal lift to help with everyday activities by reducing your risk of falling, and in the unfortunate event a fall happens, will help get you back on your feet independently or with minimal assistance. The RAYMEX® Lift looks like a four-wheeled rollator walker but is a cleverly designed 4-in-1 device: a powered lift, a transfer aid, a multifunctional mobility aid, and an exercise rehab tool. It can be used at home or in healthcare facilities. It helps people regain their independence and reduces the physical strain on caregivers. The RAYMEX® Lift is a Class I Medical Device and has a powered seat that smoothly descends to floor level and rises to 24 inches (61 cm) at the touch of a button, allowing independent or assisted transfers without strain or bending. Weighing just 36 lbs (16 kg) and supporting up to 300 lbs (136 kg), the RAYMEX® Lift offers a compact, practical alternative to traditional walkers or patient lifts. This innovative technology helps people maintain independence while improving caregiver safety in residential and healthcare settings.
Azalea Vision is a health-tech company pioneering the first intelligent, lens-embedded system designed to sense, adapt, and connect in real time. The first application is focusing on health monitoring through the tear fluid. Our technology integrates adaptive optics, custom microelectronics, and liquid-crystal systems within a contact lens—creating a scalable platform for both real-time biosensing health monitoring and vision correction.
BOYDSense is a pioneering healthtech company revolutionizing metabolic health monitoring by using non-invasive breath analysis instead of needles to track glucose and metabolic states. This breakthrough offers over 1 billion underserved individuals with pre-diabetes, early-stage Type 2 diabetes, obesity, a simple, engaging, and actionable way to manage their health. The company’s clear two-device rollout plan includes a consumer launch end 2026 followed by a medical launch in 2028, backed by proven science from 4 clinical trials, extensive intellectual property, and a highly experienced team with multiple successful exits.
BrainScope is a commercial-stage medical neurotechnology company applying artificial intelligence to brain electrical activity (EEG) to develop non-invasive, objective diagnostic tools for brain health. BrainScope developed the first AI-enabled neurology device cleared by the FDA and hold a significant first-mover advantage in this space. With commercially available products in clinical use, a robust machine and deep learning platform, and a formidable IP portfolio, BrainScope is pioneering the development of digital biomarkers to transform how brain injuries and neurological diseases are diagnosed, monitored and treated.
CIAN was founded on the discoveries of Dr. Ramani Ramchandran at the Medical College of Wisconsin. Our technology is based on the biology of a microtubule-based organelle, cilia, which plays a key role in regulating vascular stability. Based on this biology, CIAN has developed CIAN PPH, a prognostic test that predicts the risk of developing post-partum hemorrhage in pregnant women as early as the second trimester.
Conan MedTech is a medical device company with a long-term vision to empower people through medical solutions that benefit generations to come and advance the healthcare system to the next level. It is a pre-revenue startup currently in preclinical testing and validation stages, and has developed a first proof-of-concept diagnostic device called Real-Time Concussion Detector [RTCD]. Our Real Time Concussion Detection Device is a portable point of care device to diagnose soldiers, athletes and anyone with potential concussion non-invasively, accurately & rapidly using a salivary biomarker. The device assay intended for the qualitative measurement of the biomarker levels. We aim to revolutionize the diagnosis market of concussion which is estimated to be worth ~ $45 billion worldwide annually.
Dasion is an AI healthcare company built on Geometric Unified Learning (GUL), a proprietary differential-geometry–based framework that unifies voice, video, EMR, and sensor data to detect disease with exceptional accuracy using only 2% of the data required by deep learning. Supported by NSF SBIR Phase I and Phase II awards, our flagship voice-based biomarkers enable early detection of neurological, psychiatric, respiratory, and cardiovascular conditions, with a special focus on eldercare and “doctor-extended” clinical support. Unlike black-box AI, GUL is fully explainable—every prediction is traceable, transparent, and clinically interpretable. Dasion partners with health systems, senior living operators, and global organizations to deliver scalable, safe, and accessible AI-driven healthcare in the U.S. and internationally.
FreMon Scientific specializes in next generation medical devices that ensure precise thawing of life saving therapies. ZipThaw is an FDA-approved Class II medical device, made in the USA, for the warming and thawing of plasma and red blood cells in hospitals and blood banks. Data also demonstrate ZipThaw's superior recovery and viability of raw material and engineered cells for cell therapies. With a recurring revenue model, more than 200 devices have been installed in the market, from the US military to the nation’s top hospitals and academic research labs. FreMon Scientific (San Diego, CA) is raising capital to launch the Gen II ZipThaw, build out commercial capabilities, and scale the company.
GenBio AI operates at the intersection of artificial intelligence and biology, developing multiscale foundation models to understand and predict biological processes across all scales of life. Through its AI-driven Digital Organism (AIDO), the company enables predictive disease modeling, drug discovery acceleration, and bioengineering innovation. Founded by leading AI and computational biology experts from top global institutions, GenBio AI integrates pan-modal biological data to drive real-world biomedical impact. With hubs in Palo Alto, Paris, and Abu Dhabi, the company fosters international collaboration to advance AI-driven biology.
HD Medical has developed AI-Powered Devices/ Platform for early detection and monitoring of cardiovascular disease. The first-generation product HD Steth is FDA cleared and is the World's First Intelligent Stethoscope with Integrated ECG. The second-generation product called HealthyU, World's First All-in-one Remote Patient Monitoring device is expected to be FDA cleared in early 2026. It integrates a 7-Lead ECG without wires and also other limitations for monitoring cardiac parameters and other vitals.
Category-defining technology:
• First intelligent stethoscope with integrated ECG
• First handheld 7-lead ECG capable of hospital-grade signal quality
• Proprietary AI algorithms and a defensible dataset advantage
Full-platform coverage:
• Screening → Diagnosis → Monitoring; no competitor spans all three.
Heteron Biotechnologies develops hand-held breath diagnostic devices that achieve laboratory-level accuracy at a fraction of traditional testing cost. The company’s flagship H. pylori device has demonstrated 100% concordance with gold-standard 13C-UBT technology and is engineered for large-scale population screening to prevent gastric cancer. With a low-cost design, AI-assisted signal processing, and sterile disposable mouthpieces, the platform enables rapid deployment across primary care, pharmacy networks, and global health programs. Heteron is currently raising $2M to complete FDA clearance for the H. pylori testing device in the United States.
InSight Surgical Technologies, Inc. (IST, https://insightsurgicaltechnologies.com), is a medical technology company developing products to provide intraoperative guidance via image updating and quantitative fluorescence to enable faster, less invasive, more accurate, personalized treatment of tumors and to improve clinical outcomes of standard, as well as robotic and potentially all (e.g., non-cancer) surgical procedures. IST’s lead product, Image-updating (, offers seamless, unobtrusive, accurate image updates of the evolving surgical field that overcome the long-standing and widely recognized problem of brain shift that has plagued neurosurgical image guidance since its inception.
On the cutting edge of treating spine fractures, Lenoss Medical, Inc. has developed the OsteoPearl® implant system which allows surgeons to place natural bone where more bone is needed most. The OsteoPearl Biological implant, the only alternative on the market to the standard of care, is commercially available and has been used to date in over 290 spinal surgeries.
With ~ 160 issued patents, MAUI Imaging is the only ultrasound-based system that can see through and around bone, air and other barriers. MAUI’s FDA clearance uses the industry’s most successful ultrasound system, the GE Logiq, as a predicate and thus has a broad clearance and a TAM of over $10B. Given its unique capabilities, MAUI can expand on existing ultrasound use cases and image all anatomy (e.g., inside cranial vault, liver, kidney and spleen with no rib shadows, the mediastinum, the spinal cord within the spinal canal). This capability is particularly important for children as it will reduce exposure to ionizing radiation, which has been shown to have significant risk for hematologic malignancies. Lastly, MAUI captures and leverages over 1,000 times as much raw data as traditional ultrasound providing proprietary AI datasets for image interpretation and analysis in ways that traditional ultrasound cannot.
Medical 21 is a developmental-stage medical technology company dedicated to revolutionizing coronary artery bypass grafting (“CABG”) surgery. Our flagship product, the MAVERICS small-diameter synthetic regenerative graft, is designed to eliminate the need for traditional vessel harvesting, thereby making CABG procedures safer, less painful, and less expensive. By replacing autologous vessels, MAVERICS is designed to enhance patient outcomes and simplify surgical complexity.
Merge Solutions equips REMOTE Medical Device Reps, to provide their expertise from anywhere in the world. We have developed the Technology and Software, for Surgeons and Scrub Techs to use Smart Glasses and have the Remote Rep work with them, without having to be in the OR.
Micro Interventional Devices (MID) is developing the MIA™-T Percutaneous Annuloplasty System, a minimally invasive solution targeting one of structural heart disease’s largest unmet needs: tricuspid annular dilatation, the root cause of tricuspid regurgitation (TR). With more than 1.6 million U.S. patients affected and no approved annular repair technology available—while only 8,000 patients undergo surgery each year —the market opportunity for a durable, catheter-based repair is significant. MIA-T leverages MID’s proprietary PolyCor™ soft-tissue anchors to enable secure, tissue-integrating repair with minimal foreign material, while preserving future treatment options. Strong European clinical results supported FDA approval to begin the STTAR-US Pivotal Study in early 2026. MID is now raising $50M to complete this trial, receive CE Mark, and prepare for commercial launch in Europe.
Since Morphic Medical’s founding, our mission has been to alleviate the symptoms of type 2 diabetes and obesity for patients fighting these global epidemics worldwide. Our revolutionary RESET® therapy is a testament to Morphic Medical’s mission. The first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. Morphic Medical’s aim is to bridge the gap between pharmaceuticals and surgery by providing an alternate treatment option to help reduce HbA1c and weight for individuals who are underserved by drugs and injections, but for whom surgery may not be an option.
NeuWire Medical is a medical device company transforming stroke recovery using closed-loop targeted neuromodulation. Our ultra miniature, minimally invasive, leadless implantable Vagus Nerve Stimulation (VNS) system pairs with sensored rehabilitation tools and automated triggering software to enhance neuroplasticity and restore motor function in chronic stroke patients. Backed by ~$70M in non-dilutive research and development, and our breakthrough technology designation from the FDA allows NeuWire’s closed-loop system to deliver therapy real time— integrating recovery with life to maximize efficacy while enabling scalable, at-home. We are currently raising funds to execute a pivotal IDE trial and prepare for FDA approval and commercial launch.
Nitinotes developed EndoZip™, the first approved automated ESG suturing platform for the treatment of obesity. EndoZip™ recently received CE Mark treatment the of obesity, making procedures simpler, faster, and more consistent, transforming the way obesity is managed endoscopically. EndoZip™ will expand access to patients through more gastroenterologists and surgeons as a result of the easier learning curve. Earlier this year the FDA approved our IDE trial. We are currently raising expansion capital in a Series C to support our commercial and US regulatory activities.
Noor Sciences has developed a validated AI-powered, non-invasive fertility diagnostic platform to revolutionize IVF outcomes. Our Em-Lux™ system uses proprietary multi-modal imaging and trade-secret biomarkers to assess embryo and egg viability to increase IVF success rates, addressing the $48B global fertility market.
Osheru is an innovative medical device company that introduces compressive skin contouring technology—a novel approach that upends traditional skin removal methods by eliminating bleeding and the need for cautery and sutures. Our flagship product, the Ziplyft, redefines eyelid rejuvenation and transforms traditional blepharoplasty (eyelid lift) by compressing the excess skin, minimizing bruising, bleeding, and downtime. For patients, Ziplyft offers a more youthful, alert, and revitalized appearance with improved peripheral vision and a faster, more confident return to daily activities and events. For surgeons, Ziplyft provides a premium, efficient procedure requiring no cautery, no sutures, and less operating time. The result is greater consistency, reduced complications, and delighted patients.
Peerbridge Health is transforming cardiac diagnostics with a hospital-grade wearable ECG platform that brings high-fidelity cardiac data to any care setting. Our technology integrates advanced signal processing, AI-driven analytics, and a highly scalable workflow to accelerate diagnosis while improving patient experience. By operating at ultra-low cost and leveraging existing reimbursement codes, Peerbridge enables practices to expand diagnostic capacity and generate immediate economic value without disrupting established workflows. The platform is scaling across cardiology, primary care, and remote monitoring markets as providers seek solutions that are both clinically superior and financially beneficial. With strong differentiation and a robust product roadmap, Peerbridge is positioned to become a leader in next-generation cardiac care.
PredxBio is a spatial insights company powering next-generation cancer therapeutics with its AI-driven spatial biomarkers. Through its proprietary SpaceIQ™ platform, PredxBio uncovers mechanisms of action and predicts patient outcomes with over 90% accuracy—validated across multiple pharma collaborations, cancer indications, and multi-omic datasets. By transforming multiplexed biopsy images and spatial transcriptomic/proteomic data into actionable insights—and revealing the hidden network biology of cancer—PredxBio is setting new standards for biomarker discovery and clinical research. The company’s technology is actively deployed in paid engagements with leading pharmaceutical companies and research institutions, accelerating drug discovery and advancing personalized medicine for cancer patients globally. For more information, visit www.predxbio.com
Rejuvenan Global Health is a personalized, “Whole Health, Virtual Primary Care” platform company with the mission to deliver a complete solution to the healthcare consumer, rooted in Nobel Prize winning science. The Company integrates its proprietary nutrition, fitness, stress reduction and preventative telehealth plans with its telemedicine practice to provide a personalized health experience to consumers on a variety of B2C and B2B2C basis.
Retia Medical is transforming the management of at-risk patients through AI-powered cardiovascular monitoring that enables improved outcomes at lower costs. Retia serves a global opportunity of $8 Billion spanning in-hospital monitoring, predictive algorithms, and remote patient monitoring (RPM). The Company an installed base of 75 hospitals, including 500 beds at Cleveland Clinic. Retia is raising $5-8 million to launch its new clinical intelligence platform, Argos Infinity, accelerate global expansion, and pursue regulatory clearance of its new non-invasive AI algorithms.
Rheoxtech is a medical device company that has developed the RheOx™ Reperfusion System, a first-in-class patented technology designed to reduce ischemia–reperfusion injury during acute myocardial infarction (AMI). In the U.S., there are over 805,000 acute heart attacks each year, and an estimated ~40% of these patients are vulnerable to serious reperfusion injury—damage that occurs when oxygenated blood flow is restored too quickly after a blocked coronary artery is opened. RheOx enables controlled, gradual reoxygenation the heart through the culprit coronary artery at the moment of reperfusion, protecting the myocardium and preserving the hearts in AMI patients, including those with cardiogenic shock. The system is designed to integrate seamlessly into existing cath lab workflows and is used alongside current PCI tools. In initial retrospective data, RheOx was associated with an ~80% reduction in mortality and a ~70% reduction in readmission/heart failure.
Transformative Biotech is advancing patented direct-to-PCR technologies that eliminate the complex extraction step, making gold-standard molecular testing accessible anywhere. Forged during the pandemic, our platform was validated on more than 590,000 clinical samples at Summit Biolabs, a former CLIA-certified laboratory in Colorado, and is protected by U.S. Patent #12,344,889, with five additional patents pending. Our impact: enabling PCR testing for infectious diseases @ANYWARE™, improving diagnosis and treatment to help save millions of lives each year.
Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Cerebral Embolic Protection (CEP) medical device to address the unmet need for Full Brain Protection and the clinical problem of periprocedural Stroke in Structural Heart Procedures, such as Transcatheter Aortic Valve Replacement (TAVR).
TEECAD is quickly becoming a clinically inevitable part of the future of TEE procedures. As the world's first, FDA-cleared disposable camera that seamlessly connects to a transesophageal echocardiogram (TEE) probe, TEECAD provides physicians with real-time visualization during intubation and promotes more efficient and effective probe placement.